Gastroenterology and hepatology : what's new in 2023
2023 has been marked by numerous advancements in the fields of hepatology, liver transplantation, gastroenterology, and interventional endoscopy. These developments hold the promise of changing our daily practice while enhancing the diagnosis and treatment of various hepatic and gastroenterological conditions. Additionally, the European Association for the Study of the Liver (EASL) has issued recommendations for the management of hepatitis delta, acute-on-chronic liver failure, liver diseases of pregnancy, and intrahepatic cholangiocarcinoma. Risankizumab was approved by Swiss Authorities for patients with Crohn's disease and dupilumab was approved for patients with eosinophilic esophagitis. The European Society of Gastrointestinal Endoscopy (ESGE) has revised its recommendations regarding Barrett's esophagus.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Revue medicale suisse - 20(2024), 856-7 vom: 17. Jan., Seite 42-46 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Gastroentérologie et hépatologie: ce qui a changé en 2023 |
|---|
| Beteiligte Personen: |
Fraga, Montserrat [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 18.01.2024 Date Revised 18.01.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.53738/REVMED.2024.20.856-7.42 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367216531 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367216531 | ||
| 003 | DE-627 | ||
| 005 | 20240118232148.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240117s2024 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.53738/REVMED.2024.20.856-7.42 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1263.xml |
| 035 | |a (DE-627)NLM367216531 | ||
| 035 | |a (NLM)38231098 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Fraga, Montserrat |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Gastroenterology and hepatology |b what's new in 2023 |
| 246 | 3 | 3 | |a Gastroentérologie et hépatologie: ce qui a changé en 2023 |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.01.2024 | ||
| 500 | |a Date Revised 18.01.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a 2023 has been marked by numerous advancements in the fields of hepatology, liver transplantation, gastroenterology, and interventional endoscopy. These developments hold the promise of changing our daily practice while enhancing the diagnosis and treatment of various hepatic and gastroenterological conditions. Additionally, the European Association for the Study of the Liver (EASL) has issued recommendations for the management of hepatitis delta, acute-on-chronic liver failure, liver diseases of pregnancy, and intrahepatic cholangiocarcinoma. Risankizumab was approved by Swiss Authorities for patients with Crohn's disease and dupilumab was approved for patients with eosinophilic esophagitis. The European Society of Gastrointestinal Endoscopy (ESGE) has revised its recommendations regarding Barrett's esophagus | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Wakim El-Khoury, Jeanine |e verfasserin |4 aut | |
| 700 | 1 | |a Oumrani, Sarra |e verfasserin |4 aut | |
| 700 | 1 | |a Godat, Sébastien |e verfasserin |4 aut | |
| 700 | 1 | |a Vionnet, Julien |e verfasserin |4 aut | |
| 700 | 1 | |a Schoepfer, Alain |e verfasserin |4 aut | |
| 700 | 1 | |a Vieira Barbosa, Joana |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revue medicale suisse |d 2005 |g 20(2024), 856-7 vom: 17. Jan., Seite 42-46 |w (DE-627)NLM154244252 |x 1660-9379 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2024 |g number:856-7 |g day:17 |g month:01 |g pages:42-46 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.53738/REVMED.2024.20.856-7.42 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2024 |e 856-7 |b 17 |c 01 |h 42-46 | ||